|
|
|
|
|
|
Sponsors and Collaborators: |
National Institute on Drug Abuse (NIDA) State University of New York - Upstate Medical University |
Information provided by: | National Institute on Drug Abuse (NIDA) |
ClinicalTrials.gov Identifier: | NCT00148031 |
The overall goal of the research project is to improve the outcome of medical care for injection drug users (IDUs) with Hepatitis C viral (HCV) infection.
Hypothesis: An intervention designed to improve the rate of HCV treatment completion and sustained virologic response (SVR) in IDUs will increase access by integrating HCV medical care into a substance abuse treatment program.
Condition | Intervention | Phase |
Hepatitis C Liver Diseases Drug Abuse Alcoholism |
Drug: Pegylated Interferon and Ribavirin Behavioral: Psychosocial Behavioral: On-site (MMT Clinic) HCV evaluation and treatment Behavioral: Off-site HCV evaluation and treatment |
Phase IV |
MedlinePlus related topics: | Alcoholism Hepatitis Hepatitis C Liver Diseases |
ChemIDplus related topics: | Methadone Methadone hydrochloride Ribavirin Interferon alfa-2b Interferons Ethanol |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Parallel Assignment, Efficacy Study |
Official Title: | Improving Hepatitis C Treatment in Injection Drug Users |
Enrollment: | 111 |
Study Start Date: | September 2003 |
Estimated Study Completion Date: | November 2008 |
Estimated Primary Completion Date: | November 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
1: Experimental
On-site (MMT Clinic) HCV evaluation and treatment
|
Drug: Pegylated Interferon and Ribavirin
Both groups with receive the same medical intervention but offered at different locations
Behavioral: Psychosocial
Assessment of the likelihood of HCV treatment initiation and completion
Behavioral: On-site (MMT Clinic) HCV evaluation and treatment
Standard HCV treatment with Pegylated Interferon and Ribavirin
|
2: Active Comparator
Off-site (GI Clinic) HCV evaluation and treatment
|
Drug: Pegylated Interferon and Ribavirin
Both groups with receive the same medical intervention but offered at different locations
Behavioral: Psychosocial
Assessment of the likelihood of HCV treatment initiation and completion
Behavioral: Off-site HCV evaluation and treatment
Standard HCV treatment with Pegylated Interferon and Ribavirin
|
The overall goal of the proposed health services research project is to improve the outcome of medical care for injection drug users (IDUs) with Hepatitis C viral (HCV) infection. This will be done by testing an intervention designed to improve the rate of HCV treatment completion and sustained virologic response (SVR) in IDUs. This intervention will increase access by integrating HCV medical care into a substance abuse treatment program. HCV infection is endemic among IDUs, and is associated with significant medical morbidity. While antiviral treatments are improving rapidly, providing HCV medical care for IDUs remains problematic for a number of reasons. IDUs often do not have adequate access to HCV diagnosis and treatment services, and they may have co-morbid psychiatric diagnoses that affect the ability to withstand the demands of HCV treatment. Therefore, this study will also examine psychiatric disorders and psychiatric symptoms in IDUs who are infected with Hepatitis C virus.
The proposed project is a five-year program consisting of a controlled clinical trial, studying 220 patients with HCV infection enrolled in methadone maintenance treatment (MMT). The HCV Medical Care Study is a randomized trial to test the efficacy of On-site HCV Medical Care provided at the MMT program versus Off-site care at the Gastroenterology (GI) Clinic. HCV antibody positive MMT patients (N=220) will be randomly assigned to receive HCV medical services either through an integrated delivery model located on-site in the MMT clinic, or through usual off-site referral to the GI Clinic. The main outcomes will be the rates of attaining SVR and completion of HCV treatment, as well as other measures of HCV-related health outcomes and quality of life. Participants will be evaluated for Axis I psychiatric diagnoses and will complete psychiatric measures at monthly intervals throughout the study. Psychiatric diagnosis will be made using the Structured Psychiatric Interview for the DSM-IV (SCID) and psychiatric symptom severity will be assessed for depression, mania, anxiety, and psychosis. Drug use measures, and quality of life measures will also be obtained. These data are expected to yield new knowledge about the efficacy of providing on-site HVC medical care in substance abuse treatment programs. They will provide a comparison of psychiatric diagnoses and psychiatric symptom presentation in HCV positive IDUs who choose to receive HCV treatment and those who do not choose to follow through with HCV treatment and will describe changes in psychiatric symptoms before, during, and after HCV medical care. Finally, the studies will also provide information about the influence of psychiatric symptoms and drug and alcohol use on HCV medical outcomes such as treatment completion and SVR.
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, New York | |||||
Crouse Chemical Dependency Treatment Services | |||||
Syracuse, New York, United States, 13210 | |||||
SUNY Upstate Medical University - Department of Gastroenterology | |||||
Syracuse, New York, United States, 13210 |
National Institute on Drug Abuse (NIDA) |
State University of New York - Upstate Medical University |
Principal Investigator: | Steven L Batki, MD | State University of New York, Upstate Medical University - Department of Psychiatry |
State University of New York, Upstate Medical University 
  |
Crouse Hospital, Chemical Dependency Treatment Services 
  |
Batki, S.L., Canfield, K.M., Cole, C., Smyth, E., Pham, H., Ploutz-Snyder, R.; Amodio, K., Manser, K., Knoeller, G., Strutynski, K., Levine, R., Dimmock J.A. (2007) (abstract) Psychiatric diagnosis and psychiatric symptom severity in methadone treatment patients with untreated hepatitis C virus infection. American Journal on Addictions, 16:316-17.
  |
Batki, S.L., Canfield, K., Lundell, S., Levine, R., Donohue, L., Amodio, K. (oral presentation) Characteristics of opioid-dependent patients seeking Hepatitis C treatment. College on the Problems of Drug Dependence, Orlando, June.
  |
Batki, S.L., Canfield, K.M., Cole, C., Ploutz-Snyder, R., Dimmock, J., Pham, H., Smythe, E. (oral presentation) Quality of life in MMT patients with untreated HCV infection. College on the Problems of Drug Dependence, Scottsdale, June 2006.
  |
Batki, S.L., Canfield, K.M., Smyth, E., Amodio, K., Manser, K., Levine, R.A. (poster presentation) Effects of medical and psychiatric comorbidity on HCV treatment eligibility in methadone maintenance. College on the Problems of Drug Dependence, Annual Meeting, San Juan, Puerto Rico June, 2008
  |
Cornell, M.E., Peek, R.M.H., Batki, S.L. (2002) Hepatitis C in an Upstate New York methadone treatment population: Preliminary analysis. Drug and Alcohol Dependence 66:S36-37.
  |
Batki, S.L., Srinath, A.K., Cornell, M.E., Bowman, M., Peek, R.M.H., Wade, M., Dimmock, J., Abdul-Hamid, M. (2005) Depression and Substance Use in Methadone Patients with Hepatitis C. American Journal on Addictions 14:304-5.
  |
Responsible Party: | SUNY Upstate Meidcal University ( Steven Batki MD ) |
Study ID Numbers: | SUNY UMU IRB # 4929, R01 DA016764 |
First Received: | September 2, 2005 |
Last Updated: | July 10, 2008 |
ClinicalTrials.gov Identifier: | NCT00148031 |
Health Authority: | United States: Federal Government |
|
|
|
|
|
|